Clinical Benefit in Phase-I Trials of Novel Molecularly Targeted Agents: Does Dose Matter?
British Journal of Cancer - United Kingdom
doi 10.1038/sj.bjc.6605030
Full Text
Open PDFAbstract
Available in full text
Date
April 28, 2009
Authors
Publisher
Springer Science and Business Media LLC